Patent directory · USPTO A61K / A61P
Patents matching “REGENERON PHARMACEUTICALS, INC.”
837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 11020495
Humanized low affinity FCγR mouse cells
granted -
US 11020686
Methods for quantitating individual antibodies from a mixture
granted -
US 11019810
Non-human animals having a humanized signal-regulatory protein gene
granted -
US 11013220
Humanized dipeptidyl-peptidase IV (DPP4) animals
granted -
US 10995150
Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody
granted -
US 10995146
Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
granted -
US 10988537
Antibodies comprising chimeric constant domains
granted -
US 10975139
Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
granted -
US 10973879
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 10968278
Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
granted -
US 10954289
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
granted -
US 10947312
Human antibodies to GFRα3 and methods of making thereof
granted -
US 10947310
Fusion protein comprising apelin and an anti-APLNR antibody
granted -
US 10939673
Method of using mouse having a humanized cluster of differentiation 47 gene
granted -
US 10941213
Anti-TMPRSS2 antibodies and antigen-binding fragments
granted -
US 10940211
Human antibodies to S. aureus hemolysin A toxin
granted -
US 10941210
Anti-PCSK9 antibodies
granted -
US 10941208
Anti-MUC16 antibodies
granted -
US 10935554
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
granted -
US 10934349
Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody
granted -
US 10927435
Compositions for the treatment of rheumatoid arthritis and methods of using same
granted -
US 10925971
Methods of treating PRLR positive breast cancer
granted -
US 10905784
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
granted -
US 10888601
Use of a VEGF antagonist to treat angiogenic eye disorders
granted